Modeling Monthly Migraine-Day Distributions Using Longitudinal Regression Models and Linking Quality of Life to Inform Cost-Effectiveness Analysis: A Case Study of Fremanezumab in Japanese-Korean Migraine Patients-Reference-Cited by-同舟云学术

Modeling Monthly Migraine-Day Distributions Using Longitudinal Regression Models and Linking Quality of Life to Inform Cost-Effectiveness Analysis: A Case Study of Fremanezumab in Japanese-Korean Migraine Patients

Published:2023-06-15 Issue:10 Volume:41 Page:1263-1274
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Wang Xinyu,Yamato Kentaro,Kojima Yoshitsugu,Paris Josef J.,Peterse Elisabeth F. P.,Simons Martijn J. H. G.^ORCID,Bennison Craig

Funder

Otsuka Pharmaceutical

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-023-01288-1.pdf

Reference36 articles.

1. Di Tanna GL, et al. Migraine day frequency in migraine prevention: longitudinal modelling approaches. BMC Med Res Methodol. 2019;19:20. https://doi.org/10.1186/s12874-019-0664-5.

2. Di Tanna GL, et al. Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials. Health Qual Life Outcomes. 2019;17:171. https://doi.org/10.1186/s12955-019-1242-6.

3. Lipton RB, Brennan A, Palmer S, Jansen JP, Hatswell AJ, Porter JK, Di Tanna GL, Villa G, Shah N, Sapra S. Novel biologics versus conventional preventive therapies in migraine: a framework for economic evaluation. Value Health. 2017;20:A732. https://doi.org/10.1016/j.jval.2017.08.1997.

4. Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16:86–92. https://doi.org/10.1007/s11916-011-0233-z.

5. Buse DC, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52:1456–70. https://doi.org/10.1111/j.1526-4610.2012.02223.x.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective;PharmacoEconomics;2024-05-21